{"id":"teriflunomide-oral-tablet","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"8-12","effect":"Diarrhea"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-8","effect":"Hair loss (alopecia)"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Hypertension"},{"rate":"2-4","effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL973","moleculeType":"Small molecule","molecularWeight":"270.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking dihydroorotate dehydrogenase, teriflunomide depletes pyrimidine nucleotides needed for DNA and RNA synthesis, selectively suppressing the proliferation of activated T and B lymphocytes. This immunosuppressive effect reduces the inflammatory cascade underlying autoimmune diseases. The drug is the active metabolite of leflunomide and has a long half-life allowing once-daily oral dosing.","oneSentence":"Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:08.888Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Secondary progressive multiple sclerosis (SPMS)"}]},"trialDetails":[{"nctId":"NCT03709446","phase":"PHASE1, PHASE2","title":"Leflunomide in Previously Treated Metastatic Triple Negative Cancers","status":"COMPLETED","sponsor":"Joseph Sparano","startDate":"2019-04-16","conditions":"Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer","enrollment":17},{"nctId":"NCT04799288","phase":"PHASE1, PHASE2","title":"Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2021-09-24","conditions":"HAM/TSP","enrollment":24},{"nctId":"NCT05147220","phase":"PHASE3","title":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-16","conditions":"Relapsing Multiple Sclerosis","enrollment":1001},{"nctId":"NCT06141473","phase":"PHASE3","title":"Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-13","conditions":"Multiple Sclerosis","enrollment":1600},{"nctId":"NCT05156281","phase":"PHASE3","title":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-13","conditions":"Relapsing Multiple Sclerosis","enrollment":1011},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT04410991","phase":"PHASE3","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-11","conditions":"Relapsing Multiple Sclerosis","enrollment":899},{"nctId":"NCT04410978","phase":"PHASE3","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":974},{"nctId":"NCT04806737","phase":"PHASE1, PHASE2","title":"Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-04-16","conditions":"Celiac Disease","enrollment":15},{"nctId":"NCT02425644","phase":"PHASE3","title":"Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-06-04","conditions":"Multiple Sclerosis","enrollment":1133},{"nctId":"NCT04056897","phase":"PHASE2","title":"Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2019-06-07","conditions":"Multiple Sclerosis","enrollment":271},{"nctId":"NCT02201108","phase":"PHASE3","title":"Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-07-16","conditions":"Multiple Sclerosis","enrollment":166},{"nctId":"NCT05385744","phase":"PHASE3","title":"An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2021-04-05","conditions":"Multiple Sclerosis","enrollment":336},{"nctId":"NCT03198351","phase":"","title":"An Observational Study on Teriflunomide-exposed Pregnancies","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-04-25","conditions":"Multiple Sclerosis","enrollment":220},{"nctId":"NCT03856619","phase":"PHASE4","title":"To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-27","conditions":"Relapsing Multiple Sclerosis","enrollment":121},{"nctId":"NCT03122652","phase":"PHASE3","title":"Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-09-25","conditions":"Multiple Sclerosis","enrollment":125},{"nctId":"NCT03277261","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2017-09-19","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":549},{"nctId":"NCT03277248","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2017-08-25","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":545},{"nctId":"NCT00622700","phase":"PHASE3","title":"Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-02","conditions":"Multiple Sclerosis","enrollment":618},{"nctId":"NCT00803049","phase":"PHASE3","title":"Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-10","conditions":"Multiple Sclerosis","enrollment":742},{"nctId":"NCT01895335","phase":"PHASE4","title":"Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Multiple Sclerosis","enrollment":1001},{"nctId":"NCT00751881","phase":"PHASE3","title":"An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-08","conditions":"Multiple Sclerosis","enrollment":1169},{"nctId":"NCT00883337","phase":"PHASE3","title":"A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-04","conditions":"Multiple Sclerosis","enrollment":324},{"nctId":"NCT01403376","phase":"PHASE2","title":"Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-09","conditions":"Multiple Sclerosis","enrollment":128},{"nctId":"NCT00228163","phase":"PHASE2","title":"Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-01","conditions":"Multiple Sclerosis","enrollment":147},{"nctId":"NCT02046629","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-05","conditions":"Multiple Sclerosis","enrollment":12},{"nctId":"NCT01252355","phase":"PHASE3","title":"Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta","status":"TERMINATED","sponsor":"Sanofi","startDate":"2011-01","conditions":"Multiple Sclerosis Relapse","enrollment":534},{"nctId":"NCT00134563","phase":"PHASE3","title":"Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-09","conditions":"Multiple Sclerosis","enrollment":1088},{"nctId":"NCT00811395","phase":"PHASE2","title":"Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Multiple Sclerosis","enrollment":182},{"nctId":"NCT00475865","phase":"PHASE2","title":"Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-04","conditions":"Multiple Sclerosis","enrollment":123},{"nctId":"NCT00489489","phase":"PHASE2","title":"Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-05","conditions":"Multiple Sclerosis","enrollment":118},{"nctId":"NCT01487096","phase":"PHASE2","title":"Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-04","conditions":"Multiple Sclerosis","enrollment":179},{"nctId":"NCT01239459","phase":"PHASE1","title":"Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Renal Impairment","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gluten challenge"],"phase":"phase_3","status":"active","brandName":"Teriflunomide Oral Tablet","genericName":"Teriflunomide Oral Tablet","companyName":"Oslo University Hospital","companyId":"oslo-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes. Used for Relapsing-remitting multiple sclerosis (RRMS), Secondary progressive multiple sclerosis (SPMS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}